摘要
目的:观察参脉康胶囊对冠心病不稳定型心绞痛患者血清P-选择素水平的影响。方法:将纳入的70例冠心病不稳定型心绞痛患者随机分为治疗组35例(参脉康胶囊+常规药物),对照组35例(常规药物)。疗程均为28 d。观察、对比治疗前后血清P-选择素水平的变化。结果:治疗后治疗组P-选择素水平,与对照组比较,差异有统计学意义(P<0.05)。结论:参脉康胶囊对冠心病不稳定型心绞痛疗效肯定,可有效地降低冠心病不稳定型心绞痛患者血浆P-选择素水平,抑制血小板聚集和炎症反应。
Objective：To observe the reference of Shenmaikang Capsule to P-selectin levels in serum of patients with coronary heart disease unstable angina.Methods：A total of 70 patients with coronary heart disease unstable angina were randomly divided into treatment group 35 cases（Shenmaikang Capsule ＋ conventional drugs）,the control group 35 cases（conventional drugs）.Course of treatment was 28 days.The change of P-selectin serum levels before and after treatment were observed and compared.Results：After treatment,levels of P-selectin of treatment group compared with the control group was different significantly（P0.05）.Conclusion：Shenmaikang Capsule is effective for coronary heart disease unstable angina,it can significantly reduce P-selectin levels in the plasma of patients with unstable angina,inhibit platelet aggregation and inflammatory response.
出处
《中国医药导报》
CAS
2011年第20期122-123,共2页
China Medical Herald
